

Indices	Value	Pts	Chg (%)
SENSEX	33679.24	91.16	0.27
NIFTY	10389.70	40.95	0.40
SGX NIFTY*	10358.50	(64.00)	(0.62)
DOW Jones	23557.99	31.81	0.14
S&P 500	2602.42	5.34	0.21
Nasdaq	6889.16	21.80	0.32
FTSE	7409.64	(7.60)	(0.10)
CAC	5390.46	10.92	0.20
DAX	13059.84	51.29	0.39
Shanghai Composite*	3326.82	(27.00)	(0.81)
Nikkei*	22481.16	(69.69)	(0.31)
Hang Seng*	29737.45	(128.87)	(0.43)

\*As at 8.30 am

Most Active Call & Put Symbol	Strike Price	OI	Chg (%)
NIFTY	10400 CE	4695750	(6.90)
NIFTY	10300 PE	6174225	2.74

Commodity	Value	Pts	Chg (%)
NYMEX Crude (USD)	58.95	0.93	1.60
Brent Crude (USD)	63.86	0.31	0.49
Gold (INR)	29380	(59.00)	(0.20)
Silver (INR)	39241	(151.00)	(0.38)
Copper (INR)	452	3.20	0.71
Zinc (INR)	211	(0.30)	(0.14)
Cotton (INR)	18480	(40.00)	(0.22)

Currency	Value	Pts	Chg (%)
USD/Rupee	64.70	0.12	0.19
Euro/Rupee	77.15	0.65	0.85
Pound/Rupee	86.24	0.00	0.00
Euro /USD	1.18	(0.00)	(0.03)
Dollar Index	93.20	(0.02)	(0.02)

Volatility	Value	Pts	Chg (%)
CBOE VIX	9.67	(0.21)	(2.13)
India VIX	13.51	(0.36)	(2.60)

Interest Rates	Value	Bps change
India 10-Yr Yield	7.00%	1
US 10-Yr Yield	2.34%	2

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	4488.63	28832.25	408897.54
Advance (Nos)	1513(53%)	1029(52%)	NA
Declines (Nos)	1227(42%)	730(43%)	NA
Unchanged	154(5%)	68(5%)	NA

## Market Summary

The market ended on positive note on Friday. The market breadth was positive 5 gainers for every 4 losers on BSE. 1513 shares advanced whereas 1227 shares declined and 154 shares were unchanged on BSE.

BSE Sensex gained 91 points or (0.13%) to close at 33679. Nifty 50 was up 41 point or (0.4%) to settle at 10390. BSE Mid-Cap index gained 98 points or (0.6%) to settle at 16934. BSE Small-Cap index advanced 81 points or (0.5%) to settle at 18025.

Top gainer in BSE Sensex were Infosys (1.9%), M&M (1.1%) Kotak Mahindra (1.0%), Bajaj Auto (1.0%) and ITC (0.9%) whereas top loser in BSE were Tata Motors (D) (0.9%), SBI (0.8%), Hero Motocorp (0.7%), ICICI Bank (0.6%) and BHEL (0.6%).

US markets closed positive, Dow Jones Industrial Average closed at 23558, gaining 32 points (0.1%), S&P 500 was up 5 points (0.2%) to close at 2602 and Nasdaq advanced 22 points (0.3%) to close at 6889..

European markets closed mixed, FTSE was down 8 points (0.1%) to close at 7410, CAC advanced 11 points (0.2%) to close at 5390 and DAX gained 51 points (0.4%) to close at 13061.

## Macro News

- Citing low income levels, a sizeable fiscal deficit and high general government debt, S&P has kept its India rating unchanged at the lowest investment grade of 'BBB-', with a stable outlook. It said that stable outlook reflects its view that over the next 2 year India's growth will remain strong, it will maintain its sound external accounts position and added that fiscal deficits will remain broadly in line with their expectations. Welcoming government's reforms, including the rollout of GST and a planned \$32 bn capital infusion into its struggling state-run lenders, the rating agency clarified that upward pressure on the ratings could build if the government's reforms markedly improve its net general government fiscal deficit and lead to a reduction in the level of net general government debt. It also said that downward pressure on the ratings could emerge if GDP growth disappoints, bringing about a reassessment of the view on trend growth; if net general government deficit rises significantly; or if the political will to maintain India's reform agenda significantly loses momentum.

- The government is keen on sticking to the fiscal deficit target for the year and will look for ways to make up for any revenue shortfall that could hinder this plan. The thinking at the highest level of the government is that the fiscal deficit target of 3.2% of GDP for FY18 should be met, though there can be some relaxation in the consolidation roadmap beyond that.

Institutional Activity	Cash	
	24-Nov	Nov'2017
<b>FIIs (INR Crs)</b>		
Buy	4327	102591
Sell	4744	123600
<b>Net</b>	<b>(416)</b>	<b>(21009)</b>
<b>DII (INR Crs)</b>		
Buy	3390	71500
Sell	2962	63575
<b>Net</b>	<b>428</b>	<b>7926</b>

FII Derivative Statistics (NSE)				
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)	Chg (%)
INDEX FUTURES	2450.53	2101.98	338978	1.26
INDEX OPTIONS	35990.19	36006.14	1211571	0.50
STOCK FUTURES	7688.43	7924.36	1009332	(0.90)
STOCK OPTIONS	5731.89	5759.38	130625	(1.33)
<b>Total</b>	<b>51861.04</b>	<b>51791.87</b>		

Gainers & Losers		Price	Chg (%)
<b>Gainers (INR)</b>			
Infosys		1009.95	1.87
M&M		1434.70	1.05
Kotak Mahindra		1031.00	0.98
Bajaj Auto		3293.10	0.96
ITC		260.35	0.85
<b>Losers (INR)</b>			
Tata Motors (D)		240.70	(0.89)
SBI		332.25	(0.79)
Hero Motocorp		3654.65	(0.66)
ICICI Bank		317.05	(0.64)
BHEL		92.30	(0.59)

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	18024.55	80.69	0.45
S&P BSE Mid-Cap	16934.32	98.14	0.58
S&P BSE Auto	25328.36	95.45	0.38
S&P BSE BANKEX	29221.44	31.29	0.11
S&P BSE Capital Goods	18427.47	11.71	0.06
S&P BSE FMCG	10357.87	44.06	0.43
S&P BSE Healthcare	14056.60	80.32	0.57
S&P BSE IT	10936.58	92.20	0.85
S&P BSE Metals	14228.94	(85.35)	(0.60)
S&P Oil & Gas	16120.24	109.73	0.69

## Key News

### Aurobindo Pharma looks for inorganic growth prospects in East Europe

Hyderabad-based Aurobindo Pharma is looking at inorganic growth opportunities in Eastern Europe and other geographies for deeper market penetration and to secure newer technologies. Apart from acquisitions, the company is also keen to expand its product portfolio in the US and Western European markets with high-value drugs. The high-value products that are in the pipeline include oncology, hormones, depot injections, peptides, inhalers, patches and films, vaccines and biosimilars, the company said.

### Ashok Leyland increases stake in UK-based Optare by 23%

Commercial Vehicle major Ashok Leyland Ltd has increased its stake in its loss-making UK subsidiary Optare Plc by 23.20% to 98.31%. The UK arm is one of the leading manufacturers of single-decker, double-decker buses and electric buses for Britain and other markets. In 2010, as part of its plan to become one of the top 10 global bus manufacturers, ALL has entered into an agreement with Optare to acquire 26% stake for a consideration of \$7.5 million. Then in phases, it has increased its stake to 75.11% over the years. ALL has said that Optare would help the company to access technology including a modern range of mid-size and full-size city buses which can appeal to both domestic and global markets.

### Sun Pharma recalls diabetes drug in US over microbial contamination

Sun Pharma said its US-based subsidiary is recalling two lots of diabetes drug Riomet due to microbial contamination. Sun Pharmaceutical Industries Inc (SPIL), a wholly owned subsidiary of the company, is voluntarily recalling two lots of Riomet (Metformin Hydrochloride Oral Solution), to the retail level, the Mumbai-based drug major said in a statement. The product is manufactured for SPIL by a contract manufacturer, it added. The Riomet has been found to be contaminated with microbe, *Scopulariopsis brevicaulis*. The contamination was discovered during sample preparation for the antimicrobial preservative effectiveness testing (AMPET) being performed as part of the 12 month stability study interval, Sun Pharma said.

## International Data

Country	Data	Forecast	Previous
US	FOMC Member Dudley Speaks	NA	NA

Sharad Avasthi

Head - Equity Research

sharad.avasthi@spagroupindia.com

Tel.: +91-022-42895600

Ext.206

**Analyst Certification of Independence:** The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MCX for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. www.spasecurities.com.

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

**General Disclosures:** This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com) and <http://economicstimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes

#### Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
• Managing/co-managing public offering of securities	
• Investment banking/merchant banking/brokerage services	No
• products or services other than those above	
• in connection with research report	
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company:	No

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

For More Information Visit Us At : [www.spasecurities.com](http://www.spasecurities.com)

#### SPA CAPITAL SERVICES LIMITED

Investment Advisory services,  
AMFI Reg. No. ARN-007

#### SPA Capital Advisors Limited

SEBI registered Category-1  
Merchant Bankers  
SEBI Regn. No. INM000010825

#### SPA COMTRADE PRIVATE LIMITED

#### SPA INSURANCE BROKING SERVICES LTD.

Direct Broker for Life and General  
Insurance Broking  
IRDA Lic. Code No. DB053/03

#### SPA Securities Ltd

NSE Cash  
NSE Future & Option  
NSE Currency Derivatives  
BSE Cash  
BSE Currency Derivatives  
MCX-SX Cash  
MCX-SX Future & Option  
MCX-SX Currency Derivatives  
Mutual Fund  
CDSL DP  
NSDL DP  
SEBI Research Analyst

#### SEBI Reg. Nos.

INB231178238  
INF231173238  
INE231178238  
INB011178234  
INE011178234  
INB261178231  
INF261178231  
INE261178238  
ARN 77388  
IN-DP-CDSL-485-2008  
IN-DP-NSDL-316-2009  
INH100002615